CT distinguishes liver cancer mets from lung primary

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 9
Volume 18
Issue 9

Researchers in Seoul, Korea, found early-phase contrast-enhanced CT useful for differentiating pulmonary metastases from hepatocellular carcinoma and primary lung cancer. They specifically measured the attenuations of pulmonary nodules on the CT scans.

Researchers in Seoul, Korea, found early-phase contrast-enhanced CT useful for differentiating pulmonary metastases from hepatocellular carcinoma and primary lung cancer. They specifically measured the attenuations of pulmonary nodules on the CT scans.

For this retrospective study, 13 patients with pulmonary metastases from hepatocellular carcinoma and 25 patients with primary lung cancer were evaluated. Attenuation values and the size of the pulmonary nodules were measured on contrast-enhanced CT scans.

CT and clinical features were analyzed with regard to age, gender, body surface area of the patients, the attenuation values and size of the nodules, and CT machines using univariate analysis. Multiple linear regression analysis was used to eliminate confounding factors (Acta Radiol online, August 27, 2009).

According to the results, the mean attenuation value of metastatic pulmonary nodules from hepatocellular carcinoma (75.7 ± 24.9 HU) was higher than that of primary lung cancer nodules (45.8 ± 14.4 HU; P < 0.01). Other variables (age, gender, body surface area, etc) were not significant on multiple regression analysis.

When a cut-off value of 75 HU was applied, the positive predictive value for diagnosing metastatic nodules from hepatocellular carcinoma was 100%.

The authors , led by Joon-Il Choi, MD, acknowledged that a larger prospective analysis is required to confirm these positive results.

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Related Content